Sanofi-Aventis VP touts value of CRM

Share this article:
In an ever-changing marketplace, pharma marketers must always be working on ways to foster patient relationships, according to the marketing VP behind Sanofi-Aventis' blockbuster Ambien CR.

"We are so far behind other industries but the good news is that CRM can change marketing practices," said Corinne Le Goff, VP CNS marketing, Ambien CR/Rilutek, Sanofi-Aventis.
According to Le Goff, a truly balanced marketing plan should include a mass-marketing and CRM budget, since CRM is the only way marketers can really start a dialogue.

"Avoiding CRM would be a big mistake," Le Goff said. "Our goal is to educate patients. We need to understand patient attitudes and beliefs. The impact of CRM provides an opportunity to create brand loyalty. To gain a competitive advantage over other brands and increase revenue, you must increase brand awareness."
Le Goff's remarks came during the Center for Business Intelligence's ninth annual Customer Relationship Management for the Bio/Pharmaceutical Industry conference held in Brooklyn, NY in mid-October.

Le Goff explained that Sanofi-Aventis is placing customer insight as a "key driver" of its marketing efforts over the next few years.

"Mass advertising is not the way to do it," Le Goff said. "With Ambien CR, we had existing DRTV, print incentives, Web initiatives. We built a database and work just got started to convert handraisers into patients and identify different segments."

Most importantly, pharma marketers need to talk directly to the customer.

"It's a threat to our revenues and to our health. We need to understand customer value and do it better than our competition."

For Sanofi-Aventis, that means communicating across brands.

"We need to understand cross branding," Le Goff said.

Le Goff joined Sanofi-Aventis' CNS group in September 2002 as head of new product commercialization for the CNS portfolio.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...